基于肽的A组链球菌疫苗在健康志愿者中的1期随机对照试验
该单中心1期两阶段临床试验计划在加拿大埃德蒙顿招募30名18-45岁无瓣膜性心脏病证据的健康志愿者,评估J8-K4S2和p*17-K4S2两种结合肽疫苗的安全性(主要结局)与免疫原性(次要结局)。第1阶段为10人非盲安全性测试剂量阶段,第2阶段为20人三臂随机双盲对照试验,所有产品于0、3、6周给药。
要点
- J8-K4S2和p*17-K4S2是M蛋白保守区肽衍生物与SpyCEP K4S2亚单位结合CRM197的疫苗。
- 1期两阶段试验计划招募30名18-45岁健康志愿者,主要结局为疫苗安全性。
- 第2阶段为三臂随机双盲对照试验,受试者分别接种J8-K4S2、p*17-K4S2或狂犬病对照疫苗。
核心结论
- 该A组链球菌疫苗临床试验旨在研究J8-K4S2和p*17-K4S2两种新型结合肽疫苗的安全性和免疫原性。
- 若一种或两种疫苗产品显示良好的主要和次要结局,该产品将进入II期和III期研究。
研究设计与样本
- 单中心1期两阶段临床试验,地点为加拿大阿尔伯塔省埃德蒙顿,计划共招募30名18-45岁无既往瓣膜性心脏病证据的健康志愿者。
- 第1阶段为非盲安全性测试剂量阶段,招募10名志愿者,5名接种J8-K4S2、5名接种p*17-K4S2,采用非盲交错方式给药,剂量间隔至少2天。
- 第2阶段为随机双盲对照试验,招募20名志愿者,三臂分别接受J8-K4S2、p*17-K4S2或对照(狂犬病)疫苗。
- 所有产品于0、3、6周给药。
主要发现
- 主要结局为疫苗安全性。
- 次要结局为免疫原性及不同疫苗方案的比较分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Group A streptococci (Strep A) orStreptococcus pyogenes is a major human pathogen causing an estimated 500,000 deaths worldwide each year. Disease can range from mild pharyngitis to more severe infections, such as necrotizing fasciitis, septicemia, and toxic shock syndrome. Untreated, Strep A infection can lead to the serious post streptococcal pathologies of rheumatic fever/rheumatic heart disease and post-streptococcal glomerulonephritis. An effective vaccine against Strep A would have great benefits worldwide. Here, we test two products, J8 and p*17-both peptide derivatives of a highly conserved region in the M protein, in combination with the protein subunit K4S2 of SpyCEP, an IL-8 protease associated with neutrophil chemoattraction. Each peptide is individually conjugated to cross reacting material (CRM197), and the conjugated peptide vaccines are abbreviated as J8-K4S2 or p*17-K4S2. METHODS: This single-site phase I, two-stage clinical trial in Edmonton, Alberta, Canada, aims to recruit a total of 30 healthy volunteers, aged 18-45 years, without any evidence of pre-existing valvular heart disease. The trial is divided into the initial unblinded safety test dose stage (stage 1) and the randomized, double-blinded, controlled trial stage (stage 2). Stage 1 will recruit 10 volunteers-5 each to receive either J8-K4S2 or p*17-K4S2 in an unblinded, staggered fashion, whereby volunteers are dosed with intentional spacing of at least 2 days in between doses to monitor for any immediate side effects before dosing the next. Once all 5 volunteers have received 3 doses of the first test vaccine, a similar process will follow for the second test vaccine. Once safety is established in stage 1, we will proceed to stage 2, which will recruit 20 volunteers to our 3-arm randomized controlled trial (RCT), receiving either of the trial vaccines, J8-K4S2 or p*17-K4S2, or comparator (rabies) vaccine. All product dosing will be at 0, 3, and 6 weeks. The primary outcome is vaccine safety; the secondary outcome is immunogenicity and comparative analyses of the different vaccine regimens. DISCUSSION: This Strep A vaccine clinical trial aims to investigate safety and immunogenicity of two novel conjugated peptide-based vaccines, J8-KS42 and p*17-K4S2. If one or both vaccine products demonstrate favorable primary and secondary outcomes, the product(s) will move into phase II and III studies. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04882514. Registered on 2021-05-12, https://clinicaltrials.gov/study/NCT04882514 .
引用
- Meier-Stephenson V, Hawkes MT, Burton C, et al. A phase 1 randomized controlled trial of a peptide-based group A streptococcal vaccine in healthy volunteers. Trials. 2024. PMID: 39563457. doi:10.1186/s13063-024-08634-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。